Trump’s tariff policies reshape global trade, with new duties on pharmaceutical imports from China and Europe threatening supply chains and profit margins. While Canada and Mexico have temporarily avoided additional tariffs, uncertainty over U.S. trade policies puts multinational biopharma companies at risk of higher costs and supply chain disruptions. As the pharmaceutical industry braces for … Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.